期刊文献+

沙利度胺治疗胃肠道血管畸形所致消化道出血的机制研究

Study on the Mechanism of Thalidomide for the Treatment of Gastrointestinal Bleeding Caused by Gastrointestinal Vascular Malformation
下载PDF
导出
摘要 【目的】探讨沙利度胺治疗胃肠道血管畸形所致消化道出血的作用机制。【方法】采用免疫组化法检测90例GIVM 所致消化道出血患者,及30例健康人肠黏膜中促血管生成素‐2(Ang‐2)、Notch‐1、DLL4的表达;采用RT‐PCR及Western blot检测50 mg/L、100 mg/L、200 mg/L沙利度胺对HUVEC细胞Ang‐2、Notch‐1、DLL4基因mRNA及蛋白表达的影响。【结果】与溶剂对照组比较,50 mg/L沙利度胺组中Notch‐1的mRNA表达量减少,100 mg/L沙利度胺组中Ang‐2,Notch‐1的mRNA表达量减少,差异具有统计学意义( P <0.05),200 mg/L沙利度胺组中Ang‐2,Notch‐1,DII4的mRNA表达量减少,差异均有统计学意义( P <0.05)。与溶剂对照组比较,50 mg/L沙利度胺组中 Ang‐2、Notch‐1的蛋白表达量下降,100 mg/L ,200 mg/L沙利度胺组中的 Ang‐2, Notch‐1,DLL4的蛋白表达量均下降,差异都具有统计学意义( P <0.05)。GIVM组织中血管扩张扭曲。Ang‐2的表达明显增高。DLL4和Notch‐1的表达在病变组织中亦明显增高。而胃肠道血管畸形(GIVM )患者非病变组织及健康体检者正常肠黏膜组织中Ang‐2、Notch‐1、DLL4均呈弱阳性(+)或阴性表达。【结果】GIVM 与Ang‐2、DLL4和Notch‐1的表达密切相关,且沙利度胺可抑制Ang‐2、DLL4和Notch‐1的mRNA及蛋白的表达。 [Objective]To explore the action mechanism of thalidomide for the treatment of gastrointestinal bleeding caused by gastrointestinal vascular malformation (GIVM ) .[Methods]The expression of Ang‐2 ,Notchl and DLL4 in intestinal mucosa of 90 patients with gastrointestinal bleeding caused by GIVM and 30 healthy per‐sons were detected by using immunohistochemical method .RT‐PCR and Western blot were used to detect the im‐pact of 50mg/L ,100mg/L and 200mg/L thalidomide on the mRNA and protein expression of Ang‐2 ,Notchl and DLL4 gene in HUVEC cells .[Results]Compared with solvent control group ,the mRNA expression of Notch1 in 50mg/L thalidomide group was reduced ,and the mRNA expression of Ang‐2 and Notch1 in 100mg/L thalidomide group were reduced ,and there was significant difference( P 〈0 .05) .The mRNA expression of Ang‐2 ,Notch1 and DLL4 in 200mg/L thalidomide group were reduced ,and there was significant difference( P 〈0 .05) .Com‐pared with solvent control group ,the protein expression of Ang‐2 and Notch1 in 50mg/L thalidomide group were reduced ,and the protein expression of Ang‐2 ,Notch1 and DLL4 in 100mg/L and 200mg/L thalidomide group were reduced ,and there was significant difference( P 〈0 .05) .The expression of Ang‐2 in vasodilation distortion tissues of GIVM was increased obviously ,and the expression of DLL4 and Notchl in the diseased tissues was also increased obviously .The expression of Ang‐2 ,Notchl and DLL4 in non‐diseased tissues of GIVM patients and normal intestinal mucosa tissues of healthy persons were weakly positive (+ ) or negative .[Conclusion]GIVM is closely associated with the expression of Ang‐2 ,DLL4 and Notchl .Thalidomide can inhibit the mRNA and protein expression of Ang‐2 ,DLL4 and Notchl .
出处 《医学临床研究》 CAS 2014年第10期1980-1982,1985,共4页 Journal of Clinical Research
关键词 沙立度胺/治疗应用 胃肠出血/药物疗法 消化系统/血液供给 血管/畸形 Thalidomide/TU Gastrointestinal Hemorrhage/DT Digestive System/BS Blood Ves-sels/AB
  • 相关文献

参考文献11

  • 1陈慧敏,戈之铮.胃肠道血管畸形的分类、发病机制和诊治进展[J].胃肠病学,2008,13(8):499-501. 被引量:9
  • 2孙晓佳(综述),张月英(综述),张维东(审校).血管生成主要信号通路[J].国际肿瘤学杂志,2010,37(2):95-97. 被引量:5
  • 3Kerbel RS. Tumor angiogenesis[J]. N Engl J Med, 2008, 358(2) : 2039-2049.
  • 4Leslie JD, Ariza-McNaughton L, Bermange AL, et al . En- dothelial signaling by the Notch ligand Delta-like 4 restricts angiogenesis[J]. Development, 2007, 134(5): 839-844.
  • 5SiekmannAt, Lawson ND. Notch signaling limits angiogenic cell behaviour in developing zebrafish arteries [J]. Nature, 2012, 445(7): 781-784.
  • 6Gale NW, Dominguez MG, Noguera I, et al . Haploinsuffie- iency of Delta-like ligand results in embryonic lethality due tomajor defects in arterial and vascular development[J]. Proc Natl Acad Sci USA, 2004,101(45) :15949-15954.
  • 7ZhuGe Q, Zhong M. Zheng W, et al . Notch-I signaling is ac- tivated in brain arteriovenous realformations in humans[J]. Brain, 2009, 132(Pt 12): 3231-3241.
  • 8Godeschalk MF, Meusink PB, vail Buuren IIR, et al . Prima- ry balloon-assisted enteroseopy in patients with obscure gast- mintestinal bleeding: findings and outcome of therapy[J]. J Clin Gastroenterol, 2010, 44(9) :e195-200.
  • 9Tabata C, Tabata R, Kadokawa Y, et al . Thalidomide pre- vents bleomycin induced Pulmonary fibrosis in mice[J]. J Immuol, 2007,179(1) :708 -714.
  • 10Macdonald J, Porter V, Scott NW, et al . Small bowel Lym- phangiectasia and angiodysplsia a positive association: novel clinical marker or shared Pathphysiology [J]? J Clin Gastroenterol, 2010, 44(9) : 610-614.

二级参考文献56

  • 1Gaur P,Bose D,Samuel S,et al.Targeting tumor angiogenesis.Semin Oncol,2009,36(2 Suppl 1):S12-19.
  • 2Li JL,Harris AL Crosstalk of VEGF and Notch pathways in tumour angiogenesis:therapeutic implications.Front Biosci,2009,14:3094-3110.
  • 3Wang JF,Zhang X,Croopman JE,et al.Activation of vascular endothelial growth factor receptor-3 and its downstream signaling promote cell survival under oxidative stress.J Biol Chem.2004,279(26):27088-27097.
  • 4Underiner TL,Ruggeri B,Gingrich DE,et al.Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy.Curr Med Chem,2004,11 (6):731-745.
  • 5Fan F,Wey JS,McCarty MF,et al.Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells.Oncogene,2005,24 (16):2647-2653.
  • 6Lohela M,Bry M,Tammela T,et al.VEGFs and receptors involved in angiogenesis versus lymphangiogenesis.Curr Opin Cell Biol,2009,21(2)-154-165.
  • 7Pentheroudakis G,Angouridakis N,Wirtz R,et al.Transcriptional activity of human epidermal growth factor receptor family and angiogenesis effectors in locoregionally recurrent head and neck squamous cell carcinoma and correlation with patient outcome.J Oncol,2009,2009:854127.
  • 8Radtke F,Schweisguth F,Pear W.The Notch' gospel'.EMBO Rep,2005,6(12):1120-1125.
  • 9Duarte A,Hirashima M,Benedito R,et al.Dosage-sensitive requirement for mouse D114 in artery development Genes Dev,2004,18 (20):2474-2478.
  • 10Le Borgne R,Bardin A,Schweisguth F.The roles of receptor and ligand endocytosis in regulating Notch signaling.Development,2005,132:1751-1762.

共引文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部